This data is due to the fact that, in our region, the local regulatory agency strongly recommends that all patients with moderate–severe bio-naïve psoriasis should go through a biosimilar TNF blocker drug with exceptions linked to the patient’s severity status. This evidence concerns the gene TNF and psoriasis.